Tag Archives: Moderate

Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Print this page INDIANAPOLIS, March 30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis… Read More »

Amzeeq Now Available for Moderate to Severe Acne – Monthly Prescribing Reference

Amzeeq (minocycline; Foamix) topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older. Amzeeq utilizes Foamix’s proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline, a tetracycline-class drug, in a foam formulation; it… Read More »

FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne

FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne Print this page REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel… Read More »

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis Print this page NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ — AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic… Read More »

FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause

Print this page BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena… Read More »

Moderate Drinking Is A Risk Factor For Atrial Fibrillation (STUDY)

Alcohol use is common nowadays, and excessive usage among individuals continues to be high. Excessive drinking is a recognized atrial fibrillation risk factor, and now researchers have shown that mild and moderate consumption is a modifiable risk factor of significance for atrial fibrillation. They demonstrated that regular and moderate consumption of alcohol averaging 14 glasses… Read More »